Psychiatry Practice Deal Structure: How Sellers Get Paid

Psychiatry Practices

Deal Structures When Selling a Psychiatry Practice: How Sellers Actually Get Paid in 2026

Every psychiatrist who has ever looked at a Letter of Intent has had the same uncomfortable realization: the headline number on the first page is not the number that lands in your account at closing.

A buyer can offer "7x EBITDA" and a competing buyer can offer "6x EBITDA," and the second offer can put materially more cash in your pocket — and materially less risk on your shoulders — than the first. The difference is deal structure: how the purchase price is divided between cash at close, rollover equity, earnouts, seller notes, and holdbacks, and whether the transaction is built as an asset sale or a stock sale.

In 2026, with private equity platforms like LifeStance, Mindpath Health, Talkiatry, and ARC Health competing aggressively for quality psychiatry practices, deal structure has become the real battlefield. Sophisticated sellers no longer compete LOIs on multiple alone — they compete them on structure. This guide walks through every component of a psychiatry practice deal structure so you can read an LOI the way a buyer reads it, and negotiate the version that actually maximizes what you take home.

Quick Answer

A psychiatry practice sale is typically structured as either an asset sale or a stock sale, with the total purchase price divided across cash at close (usually 60–80%), rollover equity (10–30%), earnout (0–20%), and a seller note or holdback (0–10%). The exact mix depends on the buyer type — strategic, PE platform, PE add-on, or MSO — and on the seller’s risk tolerance, transition plan, and growth story.

Tony Siebel — Founder & Managing Director, Olympic M&A

Top 50 M&A Advisors 2025 · $70M+ in completed healthcare M&A transactions · 60+ published articles on healthcare consolidation · Specialized advisor for psychiatry practice sellers

What "Deal Structure" Really Means in a Psychiatry Practice Sale

Deal structure is the architecture of how a buyer pays you. The headline enterprise value is just the top of the page. Underneath it sits a stack of components, and each one carries different timing, different risk, and different upside.

In a real psychiatry transaction, a sophisticated buyer is solving for two things at once: how to pay a competitive price for the practice, and how to keep the seller economically motivated to protect the value of that practice for the next 24–60 months. Deal structure is how they balance those two goals — and it is where most sellers either capture significant additional value or quietly give it away.

Five components drive almost every psychiatry practice deal structure in the market today:

The legal form of the transaction — asset sale versus stock (or equity) sale.
Cash at close — the wire that hits your account on closing day.
Rollover equity — the portion of the deal you reinvest into the buyer's platform.
Earnouts — contingent payments tied to post-close performance.
Seller notes and holdbacks — deferred or escrowed dollars released over time.

Understanding how these pieces fit together — and which ones to push on in negotiation — is the single highest-leverage skill a seller can have before signing an LOI.

Asset Sale vs. Stock Sale: What Actually Transfers

The first structural decision in any psychiatry practice acquisition is the legal form. This decision controls what the buyer actually receives, what stays with you, and what liabilities follow the practice into the new entity.

Asset Sale

In an asset sale, the buyer creates (or uses) a new legal entity and purchases the specific assets of your practice — patient records, equipment, EHR data, contracts, leases, payer contracts (where assignable), goodwill, and the business name. Your existing legal entity continues to exist after closing; it simply no longer owns the operating practice.

Asset sales are the dominant structure in psychiatry practice transactions today, particularly with PE-backed buyers, because they give the buyer cleaner control over which assets and liabilities they assume. Things to know:

Payer contracts often must be re-credentialed or re-assigned, which can affect timing.
Real estate leases require landlord consent to assign.
Employees are typically terminated by the seller and rehired by the buyer at close.
Pre-closing liabilities (open malpractice matters, prior billing disputes, unpaid vendor invoices) generally remain with the seller's legacy entity.

Note: Tax treatment of asset vs. stock sales differs meaningfully and should be reviewed with your CPA. This guide focuses on the operational and structural mechanics only.

Stock Sale (or Equity Sale)

In a stock sale, the buyer purchases the equity of your existing legal entity. The entity continues operating exactly as it did — same EIN, same contracts, same payer agreements, same employees — but ownership transfers to the buyer.

Stock sales are less common in psychiatry, but they appear when:

The tradeoff is that the buyer inherits everything — including unknown historical liabilities — which usually means deeper diligence and more aggressive indemnification language in the purchase agreement.

Learn More

Preparing Your Psychiatry Practice for Sale

A deeper walk-through of how psychiatry-specific corporate structures interact with deal form.

Cash at Close: The Number That Actually Matters Most

Cash at close is the wire that hits your account on closing day. It is the only number in the deal that is fully certain, fully liquid, and fully yours — and it is the number a seasoned advisor will fight hardest to maximize.

In 2026 psychiatry transactions, cash at close typically falls in these ranges by buyer type:

Strategic buyer (another psychiatry group or health system): 80–95% of enterprise value.
PE platform investment: 60–75% of enterprise value, with the remainder in rollover and earnout.
PE add-on acquisition (tucked into an existing platform): 70–85% of enterprise value.
MSO transaction: 65–80% of enterprise value, with rollover into the MSO holding company common.

A buyer offering a higher headline multiple with lower cash at close is not necessarily offering a better deal. A practice with $1M of EBITDA at 7x with 60% cash at close ($4.2M) versus 6x at 85% cash at close ($5.1M) puts $900K more guaranteed dollars in the seller’s pocket on day one — even though the second offer looks “lower” on the cover page.

Cash at close is also the most negotiable lever in most LOIs. Pushing structure toward more cash at close is the single most reliable way to de-risk a deal.

Rollover Equity: The Second Bite of the Apple

Rollover equity is the portion of the purchase price you reinvest into the buyer's parent entity — typically the PE platform's holding company or an MSO topco. Instead of receiving 100% of the proceeds in cash, you receive, say, 75% in cash and "roll" the remaining 25% into equity in the combined business.

In psychiatry deals with PE buyers, rollover equity usually lands in the 10–30% range. This is one of the most important — and most misunderstood — concepts in modern healthcare M&A.

Why Buyers Want Rollover

PE buyers use rollover for three reasons. It conserves their capital. It keeps the seller economically aligned with the platform's continued growth. And it creates the "second bite of the apple" — a future liquidity event (usually 4–7 years out, when the platform itself is sold to a larger PE firm or recapitalized) where your rollover equity can pay out at a higher multiple than the original deal.

Why Sellers Should Care

A well-structured rollover can be the single most lucrative part of the entire transaction. If the PE platform grows from $20M of EBITDA at acquisition to $80M of EBITDA at exit, and the multiple expands from 7x to 10x along the way, the rollover equity can return 4–6x its original value at the platform's exit — sometimes more than the original cash at close.

But rollover is not free money. It is illiquid, it is junior to the PE firm's preferred return, and it depends entirely on the buyer executing on its thesis. Before agreeing to a rollover percentage, sellers should diligence:

The PE firm's track record with prior platforms (especially in healthcare services).
The current capital structure (how much preferred sits ahead of your common).
The expected exit timeline and the firm's prior holding periods.
Governance and information rights for rollover equity holders.
Drag-along, tag-along, and put/call provisions.

Rollover equity is where unsophisticated sellers most often get quietly disadvantaged. It is also where well-advised sellers most often build generational wealth.

Learn More

Why Private Equity Firms Buy Psychiatry Practices

How PE platforms underwrite the rollover and the eventual exit you are buying into.

Earnouts: When the Buyer Wants You to Prove It

An earnout is a contingent payment tied to the practice's performance after closing. If the practice hits certain financial or operational targets in the 12–36 months post-close, the seller earns additional consideration on top of the cash at close.

Earnouts appear in psychiatry deals most often when:

The practice has a strong but unproven growth story (e.g., a new clinic that just opened, a recently launched telepsychiatry line).
The seller is the dominant clinical producer and the buyer wants insurance against early departure.
There is a real gap between the seller's asking price and the buyer's underwriting model.

A typical psychiatry practice earnout is 10–20% of total enterprise value, measured against trailing 12-month EBITDA or revenue at one or more checkpoint dates.

How to Negotiate an Earnout That Actually Pays Out

Most earnouts that fail to pay out fail for one of three reasons: the metrics were poorly defined, the buyer controlled the operating decisions that drove the metrics, or the targets were set on an aggressive forecast the seller couldn't realistically protect. Sellers should push hard for:

Clear, simple, audit-able metrics — ideally collected revenue or normalized EBITDA, not net income.
Defined operating protections — the buyer cannot cut marketing, freeze hiring, or redirect provider capacity in ways that suppress the earnout metric.
Catch-up provisions — if Year 1 misses but Year 2 over-performs, the missed payment is recovered.
Reasonable, achievable targets — anchored to trailing performance, not a hockey-stick forecast.

Done right, an earnout is a bridge that gets the deal closed at a fair price. Done wrong, it is a 20% phantom number the seller never sees.

Seller Notes and Holdbacks: The Deferred Pieces

Two smaller but important structural pieces almost always show up in a psychiatry practice purchase agreement.

Seller Note

A seller note is a portion of the purchase price the buyer pays back to the seller over time, with interest, like a loan. In psychiatry deals, seller notes are typically 0–10% of enterprise value, with 3–5 year terms and interest rates anchored to the prevailing prime rate plus a spread.

Seller notes are most common in smaller transactions, in seller-financed deals with non-PE buyers, and in transactions where the buyer wants to preserve cash for working capital and integration spend in the first 12 months post-close.

Indemnity Holdback / Escrow

An indemnity holdback is a portion of the purchase price (typically 5–10%) held in escrow at closing to cover potential post-close claims — billing disputes, payer recoupments, undisclosed liabilities, or breaches of the seller's representations and warranties. The escrow is usually released 12–24 months after closing, minus any valid claims.

A well-prepared seller with clean financials, clean compliance, and a thorough representations and warranties insurance (RWI) policy can often reduce or eliminate the indemnity holdback entirely — putting more cash in the wire on closing day.

Buyer Type	Cash at Close	Rollover Equity	Earnout	Holdback / Seller Note	Best For
Strategic Buyer (psychiatry group, health system)	80–95%	0–10%	0–10%	5–10%	Sellers wanting clean exits with maximum certainty
PE Platform Investment	60–75%	20–30%	5–15%	5–10%	Sellers who want a second bite and platform upside
PE Add-On Acquisition	70–85%	10–20%	5–10%	5–10%	Sellers joining a proven, scaled platform
MSO Transaction	65–80%	15–25%	5–15%	5–10%	Multi-provider groups optimizing for governance + scale

These ranges are typical, not universal. Practice size, growth trajectory, provider depth, payer mix, and buyer competition in the process all move the numbers — sometimes significantly.

Download — 2026 Psychiatry Practice Market Update — Free

Current PE buyer activity, deal structures, and the platform-acquisition data shaping psychiatry M&A right now.

What Drives a Better Deal Structure (Not Just a Higher Multiple)

After advising on psychiatry practice transactions across the U.S., the same five factors separate sellers who walk away with great structures from those who accept whatever the buyer first proposes.

Run a competitive process. A single bidder is a negotiating disaster. Three to five qualified buyers competing for a quality psychiatry practice routinely lifts cash-at-close by 5–15 percentage points.

Anchor on cash at close, not headline multiple. A lower multiple with higher cash at close is almost always the safer and often the more valuable deal.

Diligence the rollover before the LOI. Treat the rollover equity as an investment decision in its own right — because that’s exactly what it is.

Negotiate the earnout’s operating protections. The seller does not control the practice after closing; the contract must protect against decisions that suppress the earnout.

Bring clean financials, clean compliance, and clean operations. Every preventable issue in diligence becomes either a price chip, a bigger holdback, or a tougher earnout. Clean practices command better structures.

Learn More

How to Sell a Psychiatry Practice — The Complete Guide

The pre-sale work that earns better deal structures.

Learn More

Psychiatry Practice EBITDA Multiples

The underlying valuation math behind every offer.

How Olympic M&A Negotiates Deal Structure for Psychiatry Practice Owners

When we represent a psychiatry practice owner, we don't optimize for the highest headline number — we optimize for the highest risk-adjusted cash in your pocket across the full lifecycle of the transaction. That means modeling every offer across cash at close, rollover, earnout, and holdback, stress-testing the platform thesis behind every rollover, and negotiating the operating protections that keep contingent dollars from quietly disappearing.

Our deal structure process for psychiatry practice transactions includes:

A pre-LOI structure model that translates every offer into apples-to-apples take-home dollars under multiple performance scenarios.
Direct diligence on the buyer's PE sponsor, prior platforms, and historical hold periods.
Negotiated rollover terms with information rights, governance protections, and put/call alignment.
Earnout architecture with audit-able metrics and clear operating protections for the seller.
RWI sourcing to reduce indemnity holdback and accelerate cash to the seller at close.

The result is a deal that pays out — fully, on time, and on the terms you negotiated.

Frequently Asked Questions About Psychiatry Practice Deal Structure

How is a psychiatry practice sale typically structured?

Most psychiatry practice sales in 2026 are structured as asset sales with a mix of cash at close (60–85%), rollover equity (10–30%), earnout (0–20%), and an indemnity holdback or seller note (5–10%). The exact mix depends on buyer type, practice size, and the seller's goals around certainty versus upside.

What is rollover equity in a psychiatry practice acquisition?

Rollover equity is the portion of the purchase price the seller reinvests into the buyer's parent platform (typically a PE-backed MSO or psychiatry group). It creates a "second bite of the apple" at the platform's eventual exit, often 4–7 years later, and is one of the most powerful wealth-building elements of a PE-backed psychiatry deal.

Is an asset sale or a stock sale better for selling a psychiatry practice?

Asset sales are the dominant structure in psychiatry transactions today because they give buyers cleaner control over assumed liabilities. Stock sales appear when payer contracts cannot be easily reassigned or when the corporate practice of medicine structure requires continuity. The right choice depends on the practice's contracts, structure, and the buyer's underwriting — and the tax implications, which should be reviewed with your CPA.

How long does an earnout typically last in a psychiatry deal?

Most psychiatry practice earnouts run 12–36 months, with one to three measurement checkpoints tied to collected revenue or normalized EBITDA. The most seller-friendly earnouts include catch-up provisions and clear operating protections that prevent the buyer from making decisions that suppress the metric.

What percentage of the deal is usually held in escrow at closing?

Indemnity holdbacks in psychiatry practice transactions typically run 5–10% of enterprise value, released 12–24 months after closing minus any valid claims. Sellers with clean financials, clean compliance, and a representations and warranties insurance (RWI) policy can often reduce or eliminate the holdback entirely.

What's the biggest deal-structure mistake psychiatry owners make?

Optimizing for headline multiple instead of cash at close. A higher multiple with a large rollover and aggressive earnout often delivers fewer guaranteed dollars than a slightly lower multiple with more cash on the wire. Always model every offer on a take-home basis under multiple scenarios.

About Tony Siebel

Founder & Managing Director, Olympic M&A

Tony Siebel is the Founder & Managing Director of Olympic M&A and one of the country's most active healthcare practice M&A advisors. Named to the Top 50 M&A Advisors of 2025, Tony has personally led more than $70M in completed healthcare M&A transactions and authored 60+ articles on healthcare practice valuation, sale readiness, and structured competitive sale processes.

Tony's expertise in the psychiatry and TMS industry is unparalleled. He understood our practice, our patients, and our growth story — and ran a process that delivered a result well above what other advisors had quoted us. He is the advisor I recommend to any psychiatrist thinking about a sale.

— Brian E., MD · Psychiatry Practice Owner

Tony advises psychiatry practice owners across the U.S. on practice valuation, sale preparation, buyer selection, and deal execution — always with the same goal: a confidential, competitive process that delivers the best possible outcome for the owner and the practice.

olympicma.com | tonys@olympicma.com | 502.360.8320

Join the Webinar — The Truth About Selling Your Psychiatry Practice in 2026–2027

A live, confidential webinar for psychiatry practice owners exploring what comes next. Insider perspective on valuation, buyer types, and how to protect what you've built. No pressure, no prep needed.